摘要
目的 探讨白细胞介素11（IL-11）在乳腺癌骨转移患者组织和血清中的表达水平和临床意义.方法 收集天津医科大学附属肿瘤医院2007年5月—2009年1月收治的180例乳腺癌患者,均经组织学病理证实;按是否发生骨转移分为乳腺癌骨转移组90例、乳腺癌无骨转移组90例.健康对照组为同期本院20名健康体检者,均排除内分泌代谢性疾病和其他慢性疾病史.抽取外周血标本,应用酶联免疫法定量检测IL-11的表达情况.同时收集乳腺病理科有完整存档资料的40例有骨转移和40例无骨转移的乳腺癌患者相应的肿瘤组织,采用组织芯片技术,应用免疫组化方法,检测肿瘤组织中IL-11的表达情况.用实时荧光定量RT-PCR分析不同乳腺组织IL-11 mRNA表达.筛选出影响患者术后生存的独立预后指标,以血清浓度中位数水平分层,并用Log-rank检验评价分层间死亡终点事件发生率.结果 IL-11的血清浓度在乳腺癌骨转移组、无骨转移组及健康对照组分别为（242.9±56.3）μg/L、（85.9±35.7） μg/L及（66.4±20.3）μg/L,差异有统计学意义（F=43.532,P＜0.05）;在骨转移组明显高于无骨转移组,（t=40.44,P＜0.001）.IL-11的高表达率在骨转移组和无骨转移组分别为57.5％和14.3％,骨转移组明显高于无骨转移组（x2=36.626,P＜0.01）.IL-11高水平的乳腺癌骨转移患者生存时间为25.2个月,短于IL-11低水平乳腺癌骨转移患者的44.6个月,差异有统计学意义（x2=9.550,P＜0.01）.结论 IL-11的表达与乳腺癌骨转移的发生相关,高表达IL-11的乳腺癌可能更易发生骨转移.
Objective To explore the expression level and clinical significance of interleukin-11 （IL-11） in the tissue and serum samples of in breast cancer bone metastasis patients.Methods Peripheral blood samples were collected from 180 breast cancer patients at Tianjin Medical University Cancer Hospital from May 2007 to January 2009 and confirmed by histological pathology.According to the occurrence of bone metastases,they were divided into 2 groups of bone metastasis （MBC-B） and without bone metastasis （PBC） （n =90 each）.Another 20 healthy controls were selected from the same hospital during the same period after excluding a history of endocrine and metabolic diseases and other chronic diseases.Peripheral blood samples were collected to detect the expression level of IL-11 by enzyme-linked immunosorbent assay.At the same time,tumor tissue samples were collected from 40 breast cancer patients with bone metastasis and 40 breast cancer patients without bone metastasis.And their complete archive data were available.The expression levels of IL-11 in tumor tissue samples were detected by tissue chip and immunohistochemistry.The IL-11 mRNA expression levels of different breast tissue samples were analyzed by fluorescent quantitative reverse transcription-polymerase chain reaction （RT-PCR）.Independent prognostic indicators of postoperative patient survival were screened and layered by the median level of serum concentration.Logrank test was employed for survival analysis.Results The serum concentrations of IL-1 1 in MBC-B,PBC and healthy control groups were （242.9 ± 56.3）,（85.9 ± 35.7） and （66.4 ± 20.3） μg/L.And it had statistically significant difference （F =43.532,P ＜ 0.05） ; MBC-B group was significantly higher than PBC group （t =40.44,P ＜0.001）.High expression rates of IL-11 were 57.5％ and 14.3％ in MBC-B and PBC groups.MBC-B group was significantly higher than PBC group （x2 =36.626,P ＜ 0.01）.The survival time of breast cancer patients with bone metastases and high levels of IL-11 was 25.2 months and it was shorter than those with bone metastases and low levels of IL-11 （44.6 months）.The difference was statistically significant （x2 =9.550,P ＜ 0.01）.Conclusion The expression level of IL-11 is associated with the occurrence of bone metastasis in breast cancer.And breast cancer with a high expression level of IL-11 may be more susceptible to bone metastases.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2014年第34期2656-2660,共5页
National Medical Journal of China
基金
国家自然科学基金（81071787）
天津医科大学科学基金（2010KY36）
关键词
乳腺肿瘤
肿瘤转移
白细胞介素11
逆转录聚合酶链反应
酶联免疫吸附测定
Breast neoplasms
Neoplasm metastasis
Interleukin 11
Reverse transcription polymerase chain reaction
Enzyme-linked immunosorbent assay
